ID
14045
Beskrivning
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583
Nyckelord
Versioner (1)
- 2016-03-23 2016-03-23 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
23 mars 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
VX-950HPC3006 NCT01571583 Study Drug Termination Ribavirin
VX-950HPC3006 NCT01571583 Study Drug Termination Ribavirin
- StudyEvent: ODM
Similar models
VX-950HPC3006 NCT01571583 Study Drug Termination Ribavirin
- StudyEvent: ODM
C1279919 (UMLS CUI [1,2])
C0877248 (UMLS CUI [2])
C2718058 (UMLS CUI [3])
C1444662 (UMLS CUI [2])
C1512714 (UMLS CUI [2])
C2349179 (UMLS CUI [2,1])
C0205466 (UMLS CUI [2,2])
C3840932 (UMLS CUI [2])
Inga kommentarer